| Today’s Big NewsMar 14, 2024 |
| By Nick Paul Taylor AstraZeneca is paying $800 million to expand into rare endocrinology, snagging itself a phase 3 candidate through the acquisition of French biotech Amolyt Pharma. The deal features $250 million in milestones tied to a regulatory event. |
|
|
|
By Eric Sagonowsky As CDMO giants Wuxi AppTec and WuXi Biologics come under mounting scrutiny for their alleged ties to Chinese government officials, they are losing a key ally in Washington, D.C. |
By Nick Paul Taylor AIDS advocates have been bringing the heat to Gilead Sciences on its trip to investor conferences in Miami. The AIDS Healthcare Foundation used the trip as a chance to re-up an attack on “greedy Gilead,” sending its advocates to protest outside two hotels hosting the events. |
By Conor Hale Better Therapeutics had previously laid off a third of its workers and instituted company-wide pay cuts as it sought reimbursements and revenue for its AspyreRx cognitive behavioral therapy app for Type 2 diabetes. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now. 
|
|
By Zoey Becker In its draft guidance, the U.K.'s cost effectiveness watchdog recognized the need for the sickle cell therapy but needs more data from Vertex on its effectiveness in an updated managed access proposal. |
By Max Bayer Genmab, coming off one of its most successful years since its inception, is transitioning to a fully integrated pharma company. The antibody maker has seen revenue quadruple since 2019. |
By Conor Hale The latest issue of the New England Journal of Medicine featured a duet of expansive studies from Guardant Health and Exact Sciences, examining their upcoming tests that aim to increase screening rates and catch earlier cases of colorectal cancer. |
By Max Bayer Astellas is ending a partnership with Cartesian and its preclinical asset, Xork. The Japanese pharma licensed the asset in January 2023, back when it was being developed by Selecta Biosciences. |
By Angus Liu About a year after launching a prior round of layoffs, Coherus BioSciences is again reducing its head count, this time by 30%. |
By James Waldron The antibody-drug conjugate craze shows no signs of slowing down any time soon, judging by Tubulis’ latest financing. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
